Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces 'Clinical Trials Update' Conference Call on Jan. 29

Share Article

Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using its electroporation-based delivery platform, announced today that it will host a conference call on Tuesday, January 29, 2008, at 9:00 AM Eastern Standard Time (EST) to update investors about the culmination of the Company's SECTA program and the five clinical trials that are underway with DNA vaccines. Inovio's CEO, Dr. Avtar Dhillon, will moderate the call. Interested parties may participate in the conference call by dialing toll-free (877) 407-9210 in the U.S. and Canada, and (201) 689-8049 outside the U.S. and Canada, and entering the conference ID #271013. An audiocast of the conference call will also be made available and may be accessed at the Company's website, http://www.inovio.com, and then clicking on "Conference Call."

News Image

    A replay of the conference call will be available through February 5, 2008, by dialing toll-free (877) 660-6853 in the U.S. and Canada, and (201) 612-7415 outside the U.S. and Canada, and entering both the account #286 and the conference ID #271013.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX:INO) is a leader in developing human applications of its electroporation technology, which uses brief, controlled electrical pulses to increase cellular uptake of DNA vaccines. Interim human data has shown that Inovio's DNA delivery technology can significantly increase gene expression and immune responses from DNA vaccines. Partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, U.S. Army, National Cancer Institute, and International Aids Vaccine Initiative. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans and that results from one study may necessarily not be reflected or supported by the results of other similar studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targeted by Inovio or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the nine months ended September 30, 2007, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald Trahan
Visit website